Skip to main content

Table 1 Baseline characteristics and angiographic features according to smoking status

From: Impact of smoking on health-related quality of Life after percutaneous coronary intervention treated with drug-eluting stents: a longitudinal observational study

Characteristic Persisitent smokers
(N = 172)
Never smokers
(N = 351)
Quitters
(N = 126)
P Value
3 Groups Persistent vs Never Persistent vs Quitter Never vs Quitter
Age (years) 60.27 ± 9.65 65.05 ± 9.32 60.21 ± 9.12 <0.001 <0.001 0.956 <0.001
Male n (%) 155 (90.1) 211 (60.1) 118 (93.7) <0.001 <0.001 0.277 <0.001
Marital status n (%) 147 (85.5) 310 (88.3) 114 (90.5) 0.405 0.356 0.195 0.509
Body mass index (kg/m2) 25.79 ± 2.80 25.12 ± 2.91 25.91 ± 2.74 0.005 0.011 0.739 0.008
Risk Factors n (%)
 Diabetes mellitus 33 (16.9) 89 (25.4) 19 (15.1) 0.015 0.029 0.679 0.021
 Hypertension 105 (61.0) 244 (69.5) 81 (64.3) 0.003 0.002 0.718 0.019
 Hypercholesterolemia 55 (32) 126 (35.9) 44 (34.9) 0.674 0.376 0.594 0.844
 Heart failure 16 (9.3) 25 (7.12) 11 (8.73) 0.808 0.529 0.865 0.712
 Impaired renal dysfunction 6 (3.5) 15 (4.3) 4 (3.2) 0.858 0.667 0.882 0.588
 Prior AMI n (%) 30 (17.4) 36 (10.3) 23 (18.3) 0.021 0.020 0.856 0.019
 Unstable angina 117 (68.0) 221 (63.0) 82 (65.1) 0.521 0.225 0.594 0.672
Left ventricular ejection fraction 65.52 ± 6.93 65.38 ± 8.84 66.28 ± 8.43 0.577 0.86 0.435 0.299
In-hospital laboratory test
 Fasting plasma glucose (mmol/L) 5.48 ± 1.55 5.77 ± 1.34 5.51 ± 1.26 0.170 0.125 0.477 0.229
 Total cholesterol (mmol/L) 4.07 ± 0.88 4.21 ± 1.35 4.16 ± 0.87 0.422 0.190 0.522 0.651
 Triglycerides (mmol/L) 1.67 ± 0.93 1.58 ± 1.15 1.75 ± 1.13 0.308 0.393 0.532 0.141
 HDL cholesterol (mmol/L) 0.96 ± 0.19 0.99 ± 0.20 0.98 ± 0.14 0.136 0.046 0.319 0.505
 LDL cholesterol (mmol/L) 2.43 ± 0.77 2.31 ± 0.82 2.44 ± 0.78 0.122 0.085 0.974 0.114
In-hospital treatments n (%)
 Antiplatalet 172 (100) 351 (100) 126 (100) 1.000 1.000 1.000 1.000
 Statins 169 (98.3) 348 (99.1) 123 (97.6) 0.441 0.370 0.699 0.187
 ACEI/ARB 110 (64.0) 215 (61.3) 82 (65.1) 0.693 0.550 0.841 0.447
 CCB 31 (18.0) 74 (21.1) 26 (20.6) 0.708 0.412 0.571 0.916
 β-blockers 87 (50.6) 190 (54.1) 66 (52.4) 0.742 0.445 0.759 0.735
No. of diseased vessels n (%)     0.429 0.185 0.892 0.528
 1 85 (49.4) 158 (45.0) 61 (48.4)     
 2 50 (29.1) 91 (25.9) 35 (27.8)     
 3 37 (21.5) 102 (29.1) 30 (23.8)     
Reference vessel diameter (mm) 2.95 ± 0.42 3.01 ± 0.40 2.96 ± 0.34 0.213 0.100 0.732 0.277
Percentage diameter stenosis (%) 85.82 ± 12.31 84.61 ± 11.22 86.86 ± 11.55 0.146 0.260 0.446 0.062
B2/C class lesion n, (%) 129 (75.0) 253 (72.1) 99 (78.6) 0.344 0.480 0.472 0.155
Predilation n,(%) 148 (86.0) 299 (85.2) 111 (88.1) 0.722 0.793 0.604 0.420
Stent diameter (mm) 3.02 ± 0.41 3.08 ± 0.39 3.02 ± 0.34 0.104 0.074 0.982 0.104
Total stent length (mm) 32.18 ± 6.53 32.36 ± 7.00 33.56 ± 6.57 0.431 0.196 0.439 0.775
Stent delivery pressure (atm) 14.50 ± 2.31 14.39 ± 2.26 14.68 ± 2.05 0.435 0.583 0.487 0.202
Postdilation n,(%) 57 (33.1) 106 (30.2) 45 (35.7) 0.491 0.495 0.644 0.254
  1. AMI acute myocardial infarction, HDL high density lipid, LDL Low density lipid, ACEI angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, CCB calcium channel blockers